Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement

Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures: 🤝 Moderna signs rare disease drug deal with Recordati: The Italian drugmaker will pay Moderna $50 million upfront and ...